Skin aging

CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned subsidiary, Claruvis Pharmaceutical Co., has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for YY003, the world's first liquid formulation of recombinant BoNT/A, packaged in a pre-filled syringe, developed for the treatment of glabellar lines. "We are thrilled to receive FDA approval to advance the novel liquid formulation of rBoNT/A (YY003) into clinical development. This liquid-formulated recombinant BoNT/A, delivered via a prefilled device, represents a safer and more convenient option for users. The combination of a super-pure, highly effective product and its ease-of-use design offers BoNT/A users an optimized solution," said Dr. Wu Yang, Chief Scientific Officer of Claruvis, who has over 20 years of experience in botulinum toxin research and development. Claruvis Pharmaceutical, one of the few pioneering biotech companies in China, has developed the world's first recombinant BoNT/A product to reach clinical studies. The company recently completed its Phase III clinical trial for treatment of medium to severe glabellar lines and achieved all the study end points. The efficacy, safety and immunogenicity profiles demonstrated in the trial have set a remarkable milestone in the field of cosmetical use of BoNTs. On September 14th, the company has also successfully dosed the first patient in a phase II clinical trial for treatment of adult upper arm spasm in China, setting another new world record utilizing recombinant BoNT/A for the therapeutic indication. The company has started its first Biologics License Application (BLA) in China, backed by a comprehensive set of successful Phase I, II, and III clinical results. Dr. Yang added, "We believe the FDA's approval of YY003 for clinical evaluation is a significant milestone towards launching a high-quality product in the Botulinum toxin market." About MingMed MingMed Biotechnology Co., Ltd. is an innovative company dedicated to the in-house discovery and development of novel drugs that address global unmet medical needs. Our R&D team is led by global top-notch scientists and specialists. Leveraging our research and development capabilities and efficient operations, we have built an internally developed product portfolio with a diverse yet synergistic suite of four major therapeutic areas, namely recombinant botulinum toxin, ophthalmic drugs, immuno-oncology drugs and pet immune drugs. Our product pipelines include a number of first-in-class drug candidates, and the major products have moved forward to commercialization. About Claruvis Pharmaceutical Claruvis, a non-wholly owned subsidiary of MingMed Biotechnology, is strategically focus on the development, production and commercialization of botulinum toxin products utilizing recombinant protein technology. The R&D team is formed by top-notch global scientists and senior American Chinese scholars with in-depth knowledge and experience in botulinum toxin products. Marking a significant milestone, Claruvis has pioneered the development of the world's first recombinant type A BoNT product on a self-developed R&D platform. Excellent operational capability supported by a globally competitive R&D platform will continue to drive Claruvis' innovation and fast development in the rBoNT area to address the vast number of unmet aesthetic and therapeutic medical needs worldwide. Contact: [email protected] SOURCE MingMed Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdown Marlborough, Massachusetts--(News - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, has been granted a skin care patent in South Korea. The patent, METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING MMP1, covers the INTASYL RXI-185 compound that treats aging and skin disorders, including photo-aging. RXI-185 is a potent silencer of MMP1 expression in the skin, interrupting ultraviolet radiation (UVR) induced collagen breakdown, thereby improving and/or slowing the progression for skin thickening, elasticity and wrinkles. This is an additional patent in a family of patents covering INTASYL compounds that target aging skin disorders. The Phio patent portfolio now consists of 81 issued patents, 77 of which cover the INTASYL siRNA gene silencing technology. The portfolio includes patents and applications broadly covering both the composition and methods of use of INTASYL compounds targeting immune checkpoint, cellular differentiation, and metabolism targets for ex vivo cell-based cancer immunotherapies. "Our patent portfolio for Phio's INTASYL siRNA technology is extensive and robust," said Robert Bitterman, CEO of Phio Pharmaceuticals. "The addition of this recent patent for treatment of photo-aging complements our current initiative in treating skin cancer." About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL® RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. For additional information, visit the Company's website, . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Examples of forward-looking statements include statements regarding the use of RXI-185 to treat skin disorders and photo-aging. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law. Contact: Phio Pharmaceuticals Corp. ir@phiopharma.com PR Contact Michael Adams Bridge View Media adams@bridgeviewmedia.com To view the source version of this press release, please visit

Board-certified dermatologist shares 5 tips for Skin Cancer Awareness Month ROSEMONT, Ill., May 21, 2024 /PRNewswire/ -- Sunburns can be painful and damaging to your skin, while also increasing your risk of skin cancer, the most common cancer in the United States and one of the most preventable. A new survey by the American Academy of Dermatology shows that one in three Americans (36%) got a sunburn in 2023, a significant increase over the previous year. Continue Reading "No matter your skin tone, you can get a sunburn if you are outside without proper protection," said Veena Vanchinathan, MD, FAAD, a board-certified dermatologist in Morgan Hill, Calif. "It's important to practice safe sun because both tanning and sunburning harms your skin. If you repeatedly experience sunburns, your skin will become more damaged over time." A new survey by the American Academy of Dermatology shows that one in three Americans (36%) got a sunburn in 2023. Post this Prevention is key. Protect your skin from the sun to prevent sunburn and reduce your risk of skin cancer and premature skin aging. Seek shade, and wear sun-protective clothing — such as long sleeves, pants, a wide-brimmed hat, and sunglasses with UV protection. Apply a broad-spectrum, water-resistant sunscreen with an SPF of 30 or higher to all skin not covered by clothing. The same AAD survey showed that fewer than 34% of Americans use sunscreen, with only one in three reapplying it every two hours, which is the recommended timeframe. As many as 27% of people who do use sunscreen tend not to reapply sunscreen at all. Since sunscreen's protective qualities wear off over time and sweat and water can wash it off the skin, it's important to reapply sunscreen to protect yourself from the sun's harmful rays and reduce your risk of sunburn. If you do get a sunburn, the first step to treating it is to get indoors and out of the sun. Once indoors, Dr. Vanchinathan and the AAD recommend following these tips to help relieve your sunburn: Take cool baths or showers to help relieve any pain. Afterward, gently pat your skin dry. Soothe your sunburn by applying moisturizer containing aloe vera or soy while your skin is still damp and whenever you feel discomfort. You can also apply calamine lotion, place a cool, damp washcloth on the affected area, or take a colloidal oatmeal bath. Take aspirin or ibuprofen to help reduce swelling and discomfort from your sunburn. Drink extra water, as having a sunburn can make you dehydrated. Do not pop sunburn blisters. A blister means you have a second-degree sunburn. Allowing blisters to heal — instead of popping them — protects you from infection. Keep blisters clean and apply petroleum jelly to protect them while they heal. If your sunburn gets worse, partner with the sun protection expert, a board-certified dermatologist. Signs of a worsening sunburn that requires medical attention include high fever, chills, or nausea, or pus or swelling of the skin, a potential sign of a skin infection. "While a sunburn is often treatable at home, symptoms occasionally require additional attention by a board-certified dermatologist," said Dr. Vanchinathan. "Not only are we able to help make you more comfortable, it's also a great time for your dermatologist to check you for signs of skin cancer." These tips are demonstrated in "How to treat a sunburn: Dermatologist tips," a video posted to the AAD website and YouTube channel. This video is part of the AAD's "Your Dermatologist Knows" series, which offers tips people can use to properly care for their skin, hair, and nails. To find a board-certified dermatologist in your area, visit aad.org/findaderm. More Information Sun protection How to perform a skin self-exam How to select a sunscreen AAD B-Roll Library About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram. SOURCE American Academy of Dermatology